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Impaired T-cell proliferation among HAART-
treated adults with suboptimal CD4 recovery in
an African cohort
Damalie Nakanjako1,2*, Isaac Ssewanyana3, Rose Nabatanzi3, Agnes Kiragga2, Moses R Kamya1, Huyen Cao4
and Harriet Mayanja-Kizza1
Abstract
Background: Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly
active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T-cell recovery despite
effective control of HIV-RNA viraemia. We evaluated CD4 T-cell proliferation among suboptimal responders and its
correlation with CD4 T-cell activation.
Methods: The magnitude of CD4 increase (difference between absolute CD4 counts at baseline and absolute CD4
counts at 4 years of ART) was grouped into 4 quartiles for the 211 patients with sustained HIV-RNA viral
suppression. Cases of ‘Suboptimal immune responders’ included patients within the lowest quartile [Median CD4
increase 165 (Range −43-298) cells/μl; n=52] and a comparison group of ‘Optimal immune responders’ was
defined as patients within the highest quartile of CD4 increase [Median CD4 increase 528 (Range 417–878) cells/μl;
n=52]. Frozen PBMC were thawed and analysed from a convenient sample of 39 suboptimal responders and 48
optimal responders after 4 years of suppressive antiretroviral therapy. T-cell activation was measured by proportions
of T-cells expressing surface marker CD38 and HLADR (CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells). T-cell
proliferation was determined by the extent of carboxyfluorescein diacetate succinimidyl ester (CFSE) dye dilution on
culture day 5 of PBMCs in the presence of antigen (SEB, PPD, CMVpp65, GagA and GagD). Samples were analyzed
on a FACS Calibur flow cytometer and flow data was analyzed using FlowJo and GraphPad.
Results: Overall, CD4 T-cell proliferation on stimulation with SEB, PPD, CMVpp65, Gag A and Gag D.antigens, was
lower among suboptimal than optimal responders; this was significant for SEB (CD4+ p=0.003; CD8+ p=0.048) and
PPD antigens (CD8+ p=0.038). Among suboptimal responders, T-cell proliferation decreased with increasing
immune activation (Negative correlation; slope = −0.13±−0.11) but not among optimal responders.
Conclusion: T-cell immune activation and exhaustion were associated with poor proliferation among suboptimal
responders to HAART despite sustained viral suppression. We recommend studies to further understand the
mechanisms leading to impaired T-cell function among suboptimal responders as well as the potential role of
immune modulation in optimizing CD4 count and functional recovery after HAART.
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Background
CD4 T-helper function remains critical to effective im-
mune responses to common infections among HIV-
infected individuals. With chronic HIV infection, CD4 T-
cell function decreases with HIV-RNA viraemia [1,2]. Evi-
dence suggests that the HIV-associated immune dysfunc-
tion is reversible with control of HIV-viraemia [2,3]. Strong
HIV-specific immune responses have been observed
among individuals receiving potent highly active antiretro-
viral therapy (HAART) for acute HIV infection [1]. Most
HIV-infected subjects exhibit a progressive rise in CD4 T-
cell counts after initiation of HAART [4]. However, up to
40% of HAART-treated individuals exhibit very poor CD4
T-cell recovery despite effective control of HIV-RNA vir-
aemia [5,6]. CD4 count measurement is the main labora-
tory tool for monitoring immune recovery in many HIV
treatment programs in sub-Saharan Africa (SSA) [7]. With
the increasing number of individuals on HAART for longer
period of time and with the emerging population of sub-
optimal responders to HAART despite viral suppression,
there is need to consider CD4 T-cell function recovery as
the ultimate measure of immune recovery. In the devel-
oped world, significant proliferative responses were ob-
served in 30-69% of individuals on suppressive HAART
[8-11]. There is paucity of data on CD4 T-cell function re-
covery within HIV treatment programs in SSA. Moreover,
persistently low T-cell function is likely to contribute to
the increased risk of opportunistic infection observed
among the individuals with suboptimal CD4 reconstitution
despite suppressive HAART [12]. This study compared
T-cell proliferation among suboptimal and optimal
responders after four years of suppressive HAART upon
in-vitro stimulation with common antigens like Staphylo-
coccus Enterotoxin B, Cytomegalovirus and the M. Tuber-
culosis antigen purified protein derive (PPD). We also
determined the correlation between T-cell proliferation
and immune activation among suboptimal responders to
HAART. Our results give insight on the persistent immune
dysfunction among patients that do not reconstitute their
CD4 counts despite long periods of HIV-RNA viral sup-
pression and emphasize the need for innovative immune
modulation interventions to optimise immune recovery in
this sub-population of HAART-treated individuals.
Methods
Study setting and participants
Between April, 2004 and April, 2005, 559 consecutive ART-
naïve HIV-infected patients, were initiated on HAART and
enrolled into the Infectious Diseases Institute (IDI) pro-
spective observational research cohort as previously de-
scribed [13]. Patients were initiated on first-line HAART at
CD4 counts ≤ 200 cells/μl according to Ugandan guidelines
for HAART initiation at the time. Drugs were provided
through the Global Fund (a generic combined formulation
of stavudine [d4T], lamivudine [3TC], and nevirapine
[NVP] and the US President’s Emergency Plan for AIDS
Relief ( a combined formulation of zidovudine [ZDV] and
3TC plus efavirenz [EFZ] or NVP). Patients with toxicity to
ZDV were changed to tenofovir [TDF]. All patients re-
ceived cotrimoxazole (or dapsone) prophylaxis according to
the national policy to provide cotrimoxazole to all people
living with HIV (PLHIV). Adherence to HAART was en-
couraged by at least 3 individual and group counseling ses-
sions. Patients were reviewed monthly by the study
physicians that evaluated among others, adherence to
medication, toxicities and acute infections. HIV RNA viral
loads, complete blood counts and CD4 lymphocyte counts
were measured 6 monthly.
Definition of suboptimal CD4 reconstitution
Various definitions have been used to describe suboptimal
CD4 reconstitution following HAART including the magni-
tude of the CD4 cell increase [14]. Kaufmann et al. defined
suboptimal CD4 reconstitution an absolute CD4 count
< 500 cells/ μl after 5 years of sustained viral loads < 1000
copies [5]. The authors thought the latter criteria would
over–estimate suboptimal immune response in our cohort
since less than one-third of all our patients had attained an
absolute CD4 count ≥ 500 cells/ μl. Therefore we used a
cohort-specific definition of suboptimal CD4 reconstitution
in order to consider the whole spectrum of CD4 recovery.
The magnitude of CD4 increase (difference between abso-
lute CD4 counts at baseline and absolute CD4 counts after
4 years of HAART), for the 211 patients with sustained
HIV-RNA viral suppression, was grouped into 4 quartiles.
Cases of ‘Suboptimal immune responders’ included pa-
tients within the lowest quartile [Median CD4 increase 165
(Range −43-298) cells/μl; n=52] and the comparison group
of ‘Optimal immune responders’ included patients within
the highest quartile of CD4 increase [Median CD4 increase
528 (Range 417–878) cells/μl; n=52]. This study compared
CD4 T-cell proliferation among suboptimal and optimal
responders. The second and third quartiles, including 104
individuals with a median CD4 increase 282 (Range 200–
415) cells/μl were considered as average immune re-
sponders and were not included in this study which looked
at the two extremes of immune recovery. Frozen PBMCs
were from a convenient sample of 39 suboptimal re-
sponders and 48 optimal responders after 4 years of sup-
pressive HAART (see Figure 1).
We excluded patients that had an opportunistic infec-
tion in the previous 6 months. Rapid tests for malaria anti-
gens, stool microscopy for intestinal helminths and a
C-reactive protein were done to exclude common causes
of immune activation in our setting. Written informed
consent was obtained from all participants. This study was
approved by national review research and ethics board;
the Uganda National Council for Science and Technology.
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The immunology assays were performed at the Cytotoxic
T-lymphocyte laboratory (CTL) at the Joint Clinical Re-
search Center (JCRC), Kampala, Uganda.
Peripheral Blood Mononuclear Cells (PBMC) separation
Fifty (50) mls of whole blood, collected in ACD-A bottles,
was processed for PBMC separation within 4 hours of col-
lection. PBMCs were separated by Ficoll-Hypaque density
configuration, washed and re-suspended in phosphate buf-
fer saline (PBS) containing heat inactivated fetal calf serum
(FCS). PBMCs were frozen and stored in Fetal Calf Serum
with 10% dimethyl sulfoxide (DMSO), in liquid nitrogen
until assay time. On day 0, cell surface staining was done
with the following antibodies; CD3 APC, CD4 PerCP-Cy5
.5, HLA-DR FITC and CD38 PE for immune activation
and PD-1 APC for immune exhaustion (BD Biosciences
San Jose, CA). Samples were analyzed on a FACS Calibur
flow cytometer (BD Biosciences, San Jose, CA). Overall, at
least 50,000 events in the CD3-positive gate were col-
lected. The gating was standardised and set using fluores-
cence minus one controls for HLADR and CD38.
T-cell proliferation assays
Cell proliferation was determined by carboxyfluorescein
diacetate succinimidyl ester (CFSE) dilution using the
CellTrace™ CFSE Cell Proliferation Kit (Invitrogen,
Carlsbad, CA), per the manufacturer’s instructions. Pre-
viously thawed PBMC, which had been rested overnight
were cultured in the presence of either, Staphylococcal
enterotoxin B (SEB) Sigma-Aldrich, St,Lois, MO, Puri-
fied Protein Derivative (PPD), Q Biogene Carlsbad, CA,
USA, CMVpp65- μL (Q Biogene Carlsbad, CA, USA),
Gag A and Gag D (NIH/NIAID repository) or un stimu-
lated at 37°C and 5% CO2, for five days. The final con-
centration of the antigens was 1μg/ml of PBMC (1
million PBMC per well), as previously optimised by our
team [15]. On day 5, the cells were harvested and
stained with CD3 APC, CD4 PE, CD8 PerCp-Cy5.5 (BD
Biosciences, San Jose, CA). The flowcytometry data analysis
was performed using FlowJo software (TreeStar, Version
X). Only data with a minimum of 10,000 acquired events of
CD3+CD4+ or CD3+CD8+ were analyzed. T-cell prolifera-
tion was determined by the extent of carboxyfluorescein
diacetate succinimidyl ester (CFSE) dye dilution on culture
day 5 of thawed PBMCs in the presence of antigen (PPD,
CMVpp65, GagA and GagD). Staphylococcal Enterotoxin B
(SEB Sigma-Aldrich, St. Louis, MO) stimulation was used
as a positive control. All the study participants demon-
strated significant proliferation following SEB stimulation.
Proliferation results ≤ background response (un stimulated
PBMC) were considered negative whereas results ≥ twice
the background values (after subtraction of background)
Disease Research cohort
559 initiated ART
69% female
Median age 38 (33-44) yrs
51% had baseline CD4 count <100 cells/ µl
74% initiated D4T+3TC+NVP & 26% initiated ZDV+3TC+EFV
252 has sustained viral suppression up to 4 years
25 died (15-HIV/AIDS-related deaths, 6 –other medical
Illnesses, 4 cause of death cannot be determined)
7 transferred out to other ART centers
5 lost to follow up
4 withdrew consent to participate in the research cohort
0 patients with a reported opportunistic infection (s) 6 months 
prior to the study
52 in the lowest quartile of 
CD4 reconstitution 
Median CD4 increase 129 
(Range -43-199) cells/µl
39 cases ‘Suboptimal’
2 did not consent
6 not available
5 PBMC not collected
104 in the 2nd & 3rd
quartiles of CD4 increase 
Median CD4 increase 282
(Range 200-415) cells/µl
This group was not included 
in the T-cell function assays
52 in the highest quartiles of 
CD4 increase 
Median CD4 increase 528
(Range 417-878) cells/µl
48 ‘Optimal’ responders
2 did not consent
3 PBMC not collected
211 patients were eligible for current study
Figure 1 Profile of patients on antiretroviral therapy within the Infectious Diseases Institute Research cohort.
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were considered positive. Figure 2 shows the gating strategy
we used to analyse T-cell proliferation using CFSE dye and
SEB antigen stimulation.
Statistical analysis
Using Prism Graph Pad 5.0 software, we compared propor-
tions of proliferated CD4+ and CD8+ T-cells among opti-
mal and suboptimal responders; using the Mann Whitney
test for non-parametric variables. P values <0.05 were con-
sidered statistically significant. We also determined the
linear correlation between T-cell proliferation and immune
activation (co-expression of CD38 and HLADR cell surface
markers).
Results
Study participants
After 4 years of follow up on HAART, 252/559 (45%) pa-
tients had sustained HIV-RNA viral suppression. Of
these, 41 were excluded due to the following reasons;
death (n=25), lost to follow-up (n=5), voluntary request
Figure 2 Gating strategy for T-cell proliferation using CFSE dye and SEB antigen stimulation. Panel A shows the gating for CD
T-lymphocytes, Panel B shows the negative control without CD4 and CD8 T-cell proliferation and Panel C shows an individual displaying CD4
and CD8 proliferation upon stimulation with SEB.
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to transfer to and voluntary termination from the study
(n=11). The median age [Inter Quartile Range (IQR)],
was 36 (31–42) years, Body Mass Index (BMI); 22 (IQR
20–72), and haemoglobin level, 13 (IQR 12–14) g/dl.
Socio-demographic characteristics of optimal and
suboptimal responders
Age, gender and HAART regimen were similar among
optimal and suboptimal responders (p value= 0.290,
0.062 and 0.340 respectively. Suboptimal responders had
lower CD4 counts at the time of HAART initiation as
wells as years after therapy (see Table 1).
T-cell proliferation after day 5 of stimulation with SEB,
PPD, GagA&D and CMVpp65 antigens
Figure 3 shows our typical analysis of T-cell proliferation
of PBMC stained labelled with fluorescent dye 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE); on
day 5 of stimulation with SEB, Gag A & D, PPD and CMV
antigens. Upon stimulation with SEB, a super-antigen, T-
cell proliferation was lower among suboptimal responders
than optimal responders to suppressive HAART; (CD4+
P=0.003 and CD8+P=0.048). Similarly, T-cell proliferation
upon stimulation with PPD was lower among suboptimal
and optimal responders and the difference was stronger
for CD8 T-cells (CD4+; p=0.136 and CD8+; p=0.038); see
Figure 4. We found a negative correlation between im-
mune activation and CD4 T-cell proliferation among
HAART-treated adults (slope −0.13); as well as a negative
correlation between CD8 T-cell exhaustion and prolifera-
tion, among suboptimal responders (see Figure 5).
Discussion
Within the context of sustained viral suppression after 4
years of HAART, we found that suboptimal responders
exhibit lower levels of T-cell proliferation than optimal
responders. We showed significant differences when
PBMCs were stimulated with SEB and PPD. Our results
are consistent with previous reports of impaired in-vitro
HIV-specific CD4 T-cell proliferation among HIV-infected
cells although these were not in a setting of suppressive
HAART[2,16,17]. In addition to HIV-specific responses,
this study analysed T-cell responses to common antigen
(SEB, PPD, CMVpp65) to which majority of HIV-infected
patients are exposed. Our findings imply that despite
sustained viral suppression, the persistently low CD4 T-
cell function is likely to predispose suboptimal responders
to opportunistic infections and severe Staphylococcus aur-
eus infections. This could explain previous reports that
HAART-treated individuals with poor CD4 recovery des-
pite viral suppression were at increased risk of opportunis-
tic infections and mortality [12]. Given the low proliferation
levels among suboptimal responders, we postulate that sub-
optimal responders could potentially benefit from longer
periods of cotrimoxazole prophylaxis for opportunistic in-
fections as well as additional vaccines of common bacterial
infections such as pneumococcal vaccines. With the in-
creasing numbers of individuals on HAART in sub-Saharan
Africa, there is clearly need for prospective studies to
understand therapeutic interventions for the emerging
population of 30-40% suboptimal responders despite viral
suppression [12,18] in order to maximise immune recovery
during first-line antiretroviral therapy.
Table 1 Characteristics of 128 patients with sustained viral suppression after 4 years of antiretroviral therapy at the
Infectious Diseases Institute research cohort
Median CD4 increase ϕ
median (range) cells/μl
Suboptimal CD4 responders
(n=39) 165 (-43-298);]
Optimal CD4 reconstitution
(n=48) 528 (Range 417-878)
P value*
Age (yrs) [median (IQR)] 37 (31-42) 35 (31-43) 0.875
Female gender [n (%)] 28 (72) 22 (46) 0.062
Baseline CD4 count cells/μl [median (IQR)]¥ 78 (2-117) 115 (97-185) 0.018
<100 cells/μl [n(%)] 26 (67) 7 (15) 0.0015
Current CD4 cells/μl [median (IQR)] 214 (190-282) 474 (438-645) <0.001
BMI [median (IQR)] 22 (20-25) 26 (22-28) 0.162
Hemoglobin [median (IQR)] 14 (12-15) 14 (13-15) 0.481
Hepatitis B positive [n] 2 1 0.911
First-line HAART regimen∞
D4T-3TC-NVP/EFZ [n (%)] 12 (31) 27 (56)
ZDV-3TC-NVP/EFZ [n (%)] 25 (64) 17 (35)
TDF-3TC-NVP/EFZ [n (%)] 2 (5) 4 (8) 0.340
*Chi square test was used for categorical variables and Kruskal-Wallis test was used for the continuous variables.
ϕThe magnitude of CD4 increase from the baseline counts was grouped into 4 quartiles; ‘Suboptimal responders’ were patients within the lowest quartile and
‘Optimal responders’ were individuals within the highest quartile of CD4 increase.
¥All patients initiated antiretroviral therapy at CD4 200 cells/μl and below.
∞ Study participants were all on their initial first-line regimen given that they had sustained viral suppression
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The mechanisms of functional impairment of surviving
CD4 and CD8 T-cells during chronic HIV infection need to
be understood to support the development of targeted inter-
ventions. For example, Boasso et al. show that Indoleanine
2,3 dioxyenase (IDO), an immunosuppressive enzyme, plays
a role in inhibition of T-cell proliferation and its in-vitro in-
hibition increased CD4 T-cell responses in PBMCs from
HIV-infected patients [16]. Immune activation–induced fi-
brosis of lymphoid tissue in advanced HIV disease is
thought to contribute to depletion of naive T-cells and in-
creased apoptosis and subsequently perpetuate cumulative
loss of T-cells that may persist despite antiretroviral therapy
[19,20]. In addition, recent evidence from mouse studies
suggests that lymphoid tissue inducer cells are a relatively
newly recognised family of innate lymphoid cells that may
have a role in CD4 T-cell responses [21]. Furthermore, HIV-
infected dendritic cells produce gp120 that contributes to
impaired CD4 T-cell immune responses in-vivo; therefore
Figure 3 Typical analysis of T-cell proliferation of peripheral blood mononuclear cells (PBMC) stained labelled with fluorescent dye 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE); on day 5 of stimulation with SEB, Gag A & D, PPD and CMV antigens.
Panels A-D show the typical presentation of T-cell proliferation up stimulation with SEB, Gag A & D, PPD and CMV antigens respectively.
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Figure 4 CD4 and CD8 T-cell proliferation up stimulation by SEB, PPD, GagA&D and CMV antigens respectively; among suboptimal
(SO) relative to optimal (OP) immune responders after 4 years of suppressive antiretroviral therapy. Panel A shows lower CD4 and CD8
proliferation among suboptimal relative to optimal responders upon SEB stimulation, Panel B shows lower CD8 proliferation among suboptimal
relative to optimal responders upon stimulation with tuberculin PPD, Panel C shows lower CD4 proliferation upon stimulation with Gag A & D
although the difference is not statistically significant and Panel D shows lower CD4 proliferation upon stimulation with CMV although the
difference is not statistically significant.
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Ugandan cohort. Panel A shows that CD4 T-cell proliferation decreases with increasing levels of immune activation and Panel B shows that CD8
T-cell proliferation reduces with increasing levels of exhaustion.
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agents that block the gp120-mediated immune suppression
could potentially modulate immune responses in HIV-
infected individuals [17] and their role in HAART-treated
adults may be worth investigation. There is clearly a need to
understand and explore the role of these mechanisms in
CD4 T-cell function recovery within the setting of long-
term suppressive HAART. This study contributes to the in-
creasing evidence that monitoring of immune activation
levels, viral loads and CD4 function recovery are relevant to
compliment the current widely used CD4 count monitoring
[3,22] in order to optimise long-term immune recovery
within HIV treatment programs in SSA.
We found that CD4 T-cell proliferation decreased with
increasing levels of immune activation. Although the exact
mechanism is yet to be understood, this data is consistent
with our previous report that immune activation and ex-
haustion were significantly associated with suboptimal CD4
recovery [18]. Similarly, CD8 T-cell proliferation reduced
with increasing immune exhaustion. We hypothesize that
in addition to low T-cell proliferative ability, the per-
sistently high immune activation and exhaustion levels
drive the inflammatory death pathways and subse-
quently the impairment in CD4 count and functional
recovery [23]; however the reverse could also be true.
We therefore need to further understand the prevalent
T-cell death pathways among suboptimal responders
with persistent immune activation.
Our findings are consistent with previous follow-up
studies in European and American cohorts that reported
failure in long-term restoration of numeric CD4 counts,
with the recovery process reaching a plateau after 4–5
years of therapy [5,24-26]. The patients in this study had
been on treatment for 4 years which is the likely period
for the plateau phenomenon. There is need for follow-
up data on specific T-cell responses from this HAART
cohort to provide the trends of CD4 count and func-
tional recovery beyond 5 years of therapy. It is also im-
portant to note that the patients we studied had initiated
HAART in the advanced stages of HIV disease which
might be a contributing factor to suboptimal immune
recovery [5,25,26] due to the collagen deposition and fi-
brosis of lymphoid tissue during later stages of HIV in-
fection [4,19,27]. It will be interesting to perform similar
assays among patients that initiate HAART at higher
CD4 counts (>350 cells as per 2012 national antiretro-
viral therapy guidelines) or during acute HIV infection,
which associated with enhanced likelihood of CD4 count
recovery [28]. Due to the limitations of the four color
flowcytometry used in this study, we were not able to
describe all the T-cell subsets including the memory T-
cells of the specific antigens used. This would probably
provide more insight into the mechanism of suboptimal
immune recovery. For example, previous studies, among
HAART-treated individuals with CMV retinitis, showed
that memory CMV-specific CD4 and CD8 T-cells ex-
panded several years after HAART initiation [29].
To date, there is no consensus on when and how to treat
immunological failure in a setting of viral suppression. Sub-
optimal responders pose several clinical questions, including
questions about the clinical risk associated with persistent
immunodeficiency and about possible interventions to opti-
mise clinical and immunological benefits of HAART
[12,30]. From a clinical point of view, it is reasonable to hy-
pothesise that adjuvant therapy with anti-immune activation
agents [31,32] may improve T-cell proliferation potential
among suboptimal responders. Our work presents an inter-
face between clinical care and basic science research. We
also add to the evidence that immune modulation could po-
tentially maximize immunological recovery during suppres-
sive antiretroviral therapy.
Conclusion
CD4 T-cell proliferation was lower among suboptimal
than optimal responders, and reduced with increasing
levels of CD4 T-cell immune activation markers. T-cell
immune activation and exhaustion were associated with
poor proliferation among suboptimal responders to
HAART despite sustained viral suppression. We recom-
mend prospective studies to understand long-term CD4
numeric and functional recovery among suboptimal re-
sponders. In addition, we recommend innovative clinical
studies to understand the effect of immune modulants
on T-cell function recovery among the emerging popula-
tions of suboptimal responders.
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